BioNTech's overall survival data show promise of potential Keytruda killer in breast cancer

BioNTech has added evidence that PD-(L)1xVEGF-A bispecifics can unseat Keytruda. The German biotech reported an 18-month overall survival rate of 69.7% in a phase 1b/2 breast cancer trial, handily beating the cross-trial benchmark and bolstering its argument that its bispecific works in a broader population.